Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Algorithm for schizophrenia in Japan

M Sato1

  • 1Department of Psychiatry, Tohoku University School of Medicine, Sendai, Japan.

Psychopharmacology Bulletin
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topography of cat medullary ventral surface hypoxic acidification.

Journal of applied physiology (Bethesda, Md. : 1985)·1992
Same author

Ion channels on synaptic vesicle membranes studied by planar lipid bilayer method.

Biophysical journal·1992
Same author

Nucleotide sequence of cDNA for porcine heme oxygenase and its expression in Escherichia coli.

Biochemistry international·1992
Same author

Immunohistochemical evidence that rat FSH cells contain beta II-subspecies of protein kinase C.

Endocrinologia japonica·1992
Same author

Postnatal ontogenesis of neurons containing GABAA alpha 1 subunit mRNA in the rat forebrain.

Brain research. Molecular brain research·1992
Same author

Immunocytochemical and in situ hybridization evidence for the coexistence of GABA and tyrosine hydroxylase in the rat locus ceruleus.

The Anatomical record·1992
Same journal

Catatonia Associated with Psychosis: A Retrospective Study of 164 Inpatients.

Psychopharmacology bulletin·2026
Same journal

Escitalopram-Induced Spasmodic Torticollis in an Early Psychosis Service: A Case Report.

Psychopharmacology bulletin·2026
Same journal

Beyond Exposure: Standardizing Buprenorphine Training in Pain Medicine Fellowship.

Psychopharmacology bulletin·2026
Same journal

Association of CBC-Derived Indices of Inflammation with Response to Glecaprevir/Pibrentasvir for PTSD.

Psychopharmacology bulletin·2026
Same journal

When Care Becomes Dangerous: Patient Assaults Against Physicians.

Psychopharmacology bulletin·2026
Same journal

Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Psychopharmacology bulletin·2026
See all related articles

This study proposes a new algorithm for treating schizophrenia and related psychotic disorders in Japan, focusing on pharmacotherapy and psychosocial interventions. The algorithm considers side effects, efficacy variations, and patient history, excluding clozapine and risperidone due to regulatory status.

Area of Science:

  • Psychiatry and Pharmacology

Background:

  • Schizophrenia and related psychotic disorders require tailored treatment strategies.
  • Current pharmacotherapy trends in Japan inform treatment selection.
  • Psychosocial therapies are crucial for managing long-term functional impairments.

Purpose of the Study:

  • To propose an algorithm for the pharmacotherapy of schizophrenia and related psychotic disorders in Japan.
  • To integrate current Japanese pharmacotherapy trends into clinical practice.
  • To outline considerations for selecting antipsychotic medications.

Main Methods:

  • Development of a treatment algorithm based on Japanese pharmacotherapy trends.
  • Inclusion of factors such as side effects, efficacy variations, and prior treatment response.
  • Consideration of blood level information where clinically relevant.

Related Experiment Videos

Main Results:

  • The proposed algorithm guides antipsychotic selection based on multiple clinical variables.
  • It emphasizes the importance of both pharmacotherapy and psychosocial interventions.
  • Clozapine and risperidone are excluded due to their current status in Japan.

Conclusions:

  • The algorithm provides a framework for evidence-based treatment of schizophrenia in Japan.
  • It highlights the need for personalized pharmacotherapy and comprehensive psychosocial support.
  • The exclusion of certain medications reflects specific regulatory and clinical considerations in Japan.